91 related articles for article (PubMed ID: 19913171)
1. Tumor-specific liposomal drug release mediated by liposomase.
Cheong I; Zhou S
Methods Enzymol; 2009; 465():251-65. PubMed ID: 19913171
[TBL] [Abstract][Full Text] [Related]
2. A bacterial protein enhances the release and efficacy of liposomal cancer drugs.
Cheong I; Huang X; Bettegowda C; Diaz LA; Kinzler KW; Zhou S; Vogelstein B
Science; 2006 Nov; 314(5803):1308-11. PubMed ID: 17124324
[TBL] [Abstract][Full Text] [Related]
3. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
4. Targeting cancer with bugs and liposomes: ready, aim, fire.
Cheong I; Huang X; Thornton K; Diaz LA; Zhou S
Cancer Res; 2007 Oct; 67(20):9605-8. PubMed ID: 17942887
[TBL] [Abstract][Full Text] [Related]
5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
6. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
7. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.
Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W
J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801
[TBL] [Abstract][Full Text] [Related]
8. Liposome encapsulation reduces cantharidin toxicity.
Chang CC; Liu DZ; Lin SY; Liang HJ; Hou WC; Huang WJ; Chang CH; Ho FM; Liang YC
Food Chem Toxicol; 2008 Sep; 46(9):3116-21. PubMed ID: 18652872
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
[TBL] [Abstract][Full Text] [Related]
10. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermia-mediated local drug delivery by a bubble-generating liposomal system for tumor-specific chemotherapy.
Chen KJ; Chaung EY; Wey SP; Lin KJ; Cheng F; Lin CC; Liu HL; Tseng HW; Liu CP; Wei MC; Liu CM; Sung HW
ACS Nano; 2014 May; 8(5):5105-15. PubMed ID: 24742221
[TBL] [Abstract][Full Text] [Related]
12. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
13. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
14. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM
J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410
[TBL] [Abstract][Full Text] [Related]
15. Bugging tumors to put drugs on target.
Juliano R
N Engl J Med; 2007 Mar; 356(9):954-5. PubMed ID: 17329705
[No Abstract] [Full Text] [Related]
16. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
17. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
18. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells.
Rouf MA; Vural I; Renoir JM; Hincal AA
J Liposome Res; 2009; 19(4):322-31. PubMed ID: 19863167
[TBL] [Abstract][Full Text] [Related]
20. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
Liao ZX; Chuang EY; Lin CC; Ho YC; Lin KJ; Cheng PY; Chen KJ; Wei HJ; Sung HW
J Control Release; 2015 Jun; 208():42-51. PubMed ID: 25637705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
